Key Takeaways
- • PolyPeptide expanding debt capacity to EUR 200 million — The Swiss contract drugmaker strengthened its credit facility in March 2026, adding ING Bank to its lending syndicate alongside existing partners Danske Bank and Zürcher Kantonalbank, signaling strong banker confidence in growth strategy.
- • Three major PE firms actively evaluating acquisition — EQT AB, KKR & Co., and Advent are all studying potential takeover opportunities for PolyPeptide, with sources indicating willingness to partner with controlling shareholder Frederik Paulsen Jr. in a take-private transaction.
- • Revenue doubling ambition drives capital deployment — PolyPeptide is targeting 2x revenue growth by 2028 (versus 2023 baseline), underpinned by EUR 110 million H1 FY2025 capex (28.2% of revenue) to complete global facility ramp-up, particularly in Belgium.
- • Strategic financing precedes potential sale process — The expanded credit facility was announced March 19, 2026, just weeks before PE takeover interest materialized, positioning the company with enhanced financial flexibility ahead of possible strategic options evaluation.
- • CDMO peptide sector attracting significant buyout attention — PolyPeptide's interest from top-tier PE reflects broader institutional capital focus on specialized contract development and manufacturing for peptide-based pharmaceuticals amid sustained sector demand.
Summary
PolyPeptide Group AG, a Swiss-listed contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients, is actively attracting takeover interest from multiple leading private equity firms as it pursues an ambitious growth strategy. According to Bloomberg and corroborated sources, EQT AB, KKR & Co., and Advent are all evaluating potential acquisitions of the company, with sources indicating that prospective buyers could partner with billionaire controlling shareholder Fredrik Paulsen Jr. in structuring a take-private transaction.
The strategic positioning for a potential sale follows a significant credit facility expansion announced on March 19, 2026. PolyPeptide expanded its existing debt package to EUR 200 million, with UBS serving as coordinator and agent for an expanded lending syndicate that now includes ING Bank alongside Danske Bank and Zürcher Kantonalbank. According to CEO Juan Jose Gonzalez, the facility expansion reflects banking partners' confidence in the company's long-term growth trajectory and provides enhanced financial flexibility to pursue the company's strategic objective of doubling 2023 revenue by 2028.
The company's capital intensity supports this ambition. In the first half of FY2025, PolyPeptide accelerated capex to EUR 110 million, representing 28.2% of revenue, to expand global manufacturing capacity and complete the ramp-up of its Belgian facility. This sustained investment program, combined with expected margin improvements and customer-funded capacity expansions, underpins the 2028 revenue doubling target. The company operates a global network of six GMP-certified facilities across Europe, the United States, and India, with shares listed on SIX Swiss Exchange (ticker: PPGN).
The convergence of strengthened financing capacity with PE takeover interest reflects a common strategic sequencing: establishing optimal financial footing before pursuing alternative ownership structures. Multiple major buyout firms circling the asset simultaneously suggests strong conviction around peptide-based pharmaceutical market tailwinds and PolyPeptide's competitive positioning as a specialized CDMO with proven execution capability on capacity expansion.
The strategic positioning for a potential sale follows a significant credit facility expansion announced on March 19, 2026. PolyPeptide expanded its existing debt package to EUR 200 million, with UBS serving as coordinator and agent for an expanded lending syndicate that now includes ING Bank alongside Danske Bank and Zürcher Kantonalbank. According to CEO Juan Jose Gonzalez, the facility expansion reflects banking partners' confidence in the company's long-term growth trajectory and provides enhanced financial flexibility to pursue the company's strategic objective of doubling 2023 revenue by 2028.
The company's capital intensity supports this ambition. In the first half of FY2025, PolyPeptide accelerated capex to EUR 110 million, representing 28.2% of revenue, to expand global manufacturing capacity and complete the ramp-up of its Belgian facility. This sustained investment program, combined with expected margin improvements and customer-funded capacity expansions, underpins the 2028 revenue doubling target. The company operates a global network of six GMP-certified facilities across Europe, the United States, and India, with shares listed on SIX Swiss Exchange (ticker: PPGN).
The convergence of strengthened financing capacity with PE takeover interest reflects a common strategic sequencing: establishing optimal financial footing before pursuing alternative ownership structures. Multiple major buyout firms circling the asset simultaneously suggests strong conviction around peptide-based pharmaceutical market tailwinds and PolyPeptide's competitive positioning as a specialized CDMO with proven execution capability on capacity expansion.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.